Contract
Exhibit 10.3(B)
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
CONFIDENTIAL
December 22, 2011
Marina Biotech, Inc.
0000 Xxxxx Xxxxx Xxxxxxx
Xxxxxxx, Xxxxxxxxxx 00000
Attn: Xxxxxxx Xxxxxx, Chief executive Officer
Re: Agreement re Option Compound and miR-34 Sequences
Dear Xxxxxxx:
As you know, Xxxxx Therapeutics, Inc. (“MirnaRx”) and Marina Biotech, Inc. (“Marina Bio”) are entering into that certain License Agreement effective as of the date set forth above (the “License Agreement”). This letter agreement is that certain Side Agreement referred to in the License Agreement, and it sets forth the RNA oligonucleotide sequences of certain MirnaRx Compounds which are covered by rights under the Licensed Agreement.
The Parties hereby agree that the list of RNA oligonucleotide sequences attached as the Appendix of this letter agreement comprises sequences of the Option Compounds and miR-34, as such terms are used in the Licensed Agreement, and that such list may be amended by MirnaRx as provided in Section 2.6 of the Licensed Agreement, to [***]. The Parties further agree that such sequences are the highly confidential information of MirnaRx, and Marina Bio shall not disclose such sequences to any third party or use them for any purpose outside of the License Agreement.
|
AGREED TO BY |
Xxxxx Therapeutics, Inc. | |
|
|
| |
|
|
| |
|
|
Signature: |
/s/ Xxxx Xxxxxxx |
|
|
|
Xxxx Xxxxxxx, M.D., X.Xx. |
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
Marina Biotech, Inc. | |
|
|
| |
|
|
| |
|
|
Signature: |
/s/ Xxxxxxx Xxxxxx |
|
|
|
Xxxxxxx Xxxxxx |
|
|
|
Chief Executive Officer |
APPENDIX
Option Compound Sequences:
[***]
miR-34 Sequence:
[***]
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
